U.S. Markets open in 2 hrs 32 mins

Nektar Therapeutics Inc (NKTR) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Nektar Therapeutics Inc (NKTR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain. Nektar Therapeutics Inc has a market cap of $6.6 billion; its shares were traded at around $38.13 with a P/E ratio of 9.64 and P/S ratio of 5.47. Nektar Therapeutics Inc had annual average EBITDA growth of 1.30% over the past ten years.


For the last quarter Nektar Therapeutics Inc reported a revenue of $39.8 million, compared with the revenue of $95.47 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.2 billion, an increase of 287.8% from last year. For the last five years Nektar Therapeutics Inc had an average revenue growth rate of 38.3% a year.

The reported diluted earnings per share was $3.78 for the year, compared with the loss per share of $0.42 in the previous year. The Nektar Therapeutics Inc enjoyed an operating margin of 57.65%, compared with the operating margin of -14.19% a year before. The 10-year historical median operating margin of Nektar Therapeutics Inc is -74.45%. The profitability rank of the company is 7 (out of 10).

At the end of the fiscal year, Nektar Therapeutics Inc has the cash and cash equivalents of $194.9 million, compared with $4.76 million in the previous year. The long term debt was $247.0 million, compared with $245.2 million in the previous year. The interest coverage to the debt is at a comfortable level of 16.1. Nektar Therapeutics Inc has a financial strength rank of 8 (out of 10).

At the current stock price of $38.13, Nektar Therapeutics Inc is traded at 42.6% discount to its historical median P/S valuation band of $66.43. The P/S ratio of the stock is 5.47, while the historical median P/S ratio is 9.54. The stock lost 54.9% during the past 12 months.

CEO Recent Trades:

  • President & CEO Howard W Robin sold 108,882 shares of NKTR stock on 02/21/2019 at the average price of $42.19. The price of the stock has decreased by 9.62% since.

CFO Recent Trades:

  • SVP & CFO Gil M Labrucherie sold 3,592 shares of NKTR stock on 02/19/2019 at the average price of $42.39. The price of the stock has decreased by 10.05% since.

Directors and Officers Recent Trades:

  • SVP & Chief Accounting Officer Jillian B. Thomsen sold 1,808 shares of NKTR stock on 02/19/2019 at the average price of $42.39. The price of the stock has decreased by 10.05% since.
  • SVP & COO John Nicholson sold 3,822 shares of NKTR stock on 02/19/2019 at the average price of $42.39. The price of the stock has decreased by 10.05% since.
  • SVP Pharma Dev & Mfg Ops Maninder Hora sold 2,386 shares of NKTR stock on 02/19/2019 at the average price of $42.39. The price of the stock has decreased by 10.05% since.
  • SVP & Chief Scientific Officer Stephen K Doberstein sold 3,310 shares of NKTR stock on 02/19/2019 at the average price of $42.39. The price of the stock has decreased by 10.05% since.
  • SVP & Chief Accounting Officer Jillian B. Thomsen sold 16,119 shares of NKTR stock on 02/04/2019 at the average price of $42.16. The price of the stock has decreased by 9.56% since.

For the complete 20-year historical financial data of NKTR, click here.

This article first appeared on GuruFocus.